Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders (AripfMRI)

This study has been completed.
Duke University
Information provided by (Responsible Party):
Linmarie Sikich, MD, University of North Carolina, Chapel Hill Identifier:
First received: December 4, 2009
Last updated: February 7, 2014
Last verified: February 2014

December 4, 2009
February 7, 2014
August 2009
January 2011   (final data collection date for primary outcome measure)
Baseline and Week 8scores on Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version [ Time Frame: Baseline ("Pre-Dose") to 8 Weeks ("Post-Dose") ] [ Designated as safety issue: No ]
The Children's Yale-Brown Obsessive Compulsive Scale - Pervasive Developmental Disorder Version (CY-BOCS-PDD) is a clinician-rated interview designed to evaluate repetitive behavior in children with pervasive developmental disorders (PDDs). It is a modification of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), developed to assess typically-developing children with obsessive compulsive behavior. Because of language limitations in children with PDDs the CY-BOCS—PDD only includes the five compulsion items: Time Spent, Interference, Distress, Resistance of repetitive behavior, and Control of repetitive behavior. Each item is rated from 0 (none) through 4 (extreme), and scores can range from 0 to 20, with higher scores reflecting more severe symptoms. Usually a score > than 8 is considered clinically significant.
RBS-R (Repetitive Behavior Scale - Revised) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01028820 on Archive Site
Total Repetitive Behavior Scale - Revised (RBS_R) [ Time Frame: baseline week 0, 8 weeks ] [ Designated as safety issue: No ]

The RBS-R is an assessment that includes Sameness, Self-Injurious Behavior, Ritualistic, Compulsive, and Restrictive Behavior subscales. The assessments are completed by caregivers for the past week, with consideration of frequency,ease of redirecting and extent to which behavior interferes with functioning compared to a typically developing child of the same age and gender. Scores are rated from 0 - behavior does not occur to 3 - behavior occurs and is a serious problem. There are 43 items and 5 subscales. Higher scores indicate greater symptom severity. total score is the sum of all items in all subscales.

The subscales are stereotyped behaviors 6 items, self-injurious behaviors 8 items, Compulsive behaviors- 8 items, Ritualistic Behaviors 6 items, Sameness 11 items, restricted behaviors 4 items.Total score ranges from 0 to 129.

CY-BOCS (Children's Yale-Brown Obsessive Compulsive Scale) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Not Provided
Not Provided
FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms

This is an 8 week research study of aripiprazole (abilify) which is used to reduce irritable behaviors in autism spectrum disorders. All participants will receive active study medication. Participants will also receive diagnostic and cognitive evaluations at no cost. Participants will be required to undergo two fMRI (functional magnetic resonance imaging scans) where we will take pictures of your brain while performing simple tasks.

Not Provided
Phase 4
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Autism Spectrum Disorder
Drug: Aripiprazole
8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
Other Name: Abilify
Experimental: Open-Label, Flexible-Dose Aripiprazole
This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
Intervention: Drug: Aripiprazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • male or female of any race or ethnicity
  • ambulatory status (outpatient) at time of consent
  • age 10-55 inclusive at time of consent
  • clinical diagnosis of autism spectrum disorder and meets screening criteria on the Social Communication Questionnaire as well as either the Autism Diagnostic Observation Schedule (ADOS) or the Autism Diagnostic Interview-Revised (ADI-R) administered by raters trained to research reliability.
  • estimated IQ greater than 70 and capable of making an informed decision based on assessment of their understanding and judgment
  • Children's Yale-Brown Obsessive Compulsive Scale: Modified for Pervasive Developmental Disorders (PDD-CYBOCS) > 8 as assessed during telephone screening.
  • Free of psychoactive medication for at least: one month for fluoxetine; two weeks for other SSRIs and neuroleptics; and five days for stimulants prior to MRI scanning [excepting stable doses (greater than three months duration) of anticonvulsant medication for seizure disorder]
  • Currently taking psychoactive medication that is not providing sufficient relief of repetitive behaviors and willing to discontinue all psychoactive medication for the duration of the study.
  • Judged reliable for medication compliance and agreeing to keep follow-up study appointments.

Exclusion Criteria:

  • Age less than 10 years or greater than 55 years at time of consent
  • Estimated IQ less than 70
  • Uncontrolled epilepsy (seizure within 6 months prior to consent)
  • Presence of medical conditions that might interfere with participation, or where participation would be contraindicated.
  • History of neurological injury: head trauma, poorly-controlled seizure disorder (seizure within the preceding six months), stroke, prior neurosurgery, or under the care of a neurologist or neurosurgeon as determined by interview
  • History of claustrophobia
  • Implanted or irremovable metal in the body (including certain tattoos and permanent make-up).
  • Current pregnancy in females
  • Inability to communicate satisfactorily and directly (without a translator) in English
  • Medical contraindications to aripiprazole therapy as determined by history (including induction of neuroleptic malignant syndrome, dystonic reaction, or known drug allergy)
  • Ongoing need for psychoactive medication other than study medication [excepting stable doses (greater than 3 months duration) of anticonvulsant medication for seizure disorder or diphenhydramine for sleep
  • prior history of aripiprazole treatment failure at appropriate doses and duration
  • clinically significant low white blood cell count at baseline
10 Years to 55 Years
Contact information is only displayed when the study is recruiting subjects
United States
090795, K23MH081285
Linmarie Sikich, MD, University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
  • Duke University
  • National Institute of Mental Health (NIMH)
Principal Investigator: Linmarie Sikich, MD University of North Carolina
Principal Investigator: Gabriel Dichter, PhD University of North Carolina and Duke University
Study Director: Cheryl O Alderman, BS University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP